Articles tagged with Colorectal Cancer
A recent study found that a protein called URI degrades p53, leading to uncontrolled cell proliferation and tumour formation. Researchers have identified URI as a crucial regulator of p53 levels, which may be associated with environmental factors such as poor diet.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers found AI outperformed physicians in answering GI cancer questions, with oncologists preferring ChatGPT's responses nearly 80% of the time. Additionally, fewer patients are getting surgery for benign colon polyps as endoscopic techniques rise, reducing serious complications and mortality rates.
New studies showcase radiotherapy's potential as a curative treatment for rectal cancer, offering safer alternatives to surgery. Reduced-dose treatments and immunotherapy-combined regimens have improved tumour control and reduced side effects.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Flinders University researchers found that most people, regardless of age, want more frequent bowel cancer surveillance. A faecal test may provide reassurance for those at risk, particularly younger adults with a higher fear of bowel cancer.
A recent study reveals that a specific genetic variation affects the adherence of an anaerobic bacterium to tumor cells, promoting colorectal cancer progression. The study highlights the complex dynamics between host genetics and intratumoral microbiota in CRC progression.
A liquid biopsy-based assay detected signs of recurrence prior to imaging and provided prognostic value in patients with resectable colorectal cancer. The study found that ctDNA levels could predict clinical relapse, and earlier detection may help avoid unnecessary chemotherapy.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
A topical BRAF-inhibiting gel, LUT014, improved acneiform rash in 69% of patients with grade 2 or 3 rash and received an EGFR-targeted antibody. The treatment also showed a 33% success rate for the placebo arm, but was associated with similar adverse events.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
A 20-year initiative that offered flexible screening options at a major health system doubled screening rates and cut cancer incidence by a third, halving deaths. The program eliminated racial disparities in outcomes, with Black patients' deaths declining from 52.2 to 23.5 per 100,000.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.
Researchers identify colibactin, a bacterial toxin that alters DNA, as a potential trigger for early-onset colorectal cancer. Exposure to colibactin in childhood may imprint a distinct genetic signature on colon cells, increasing the risk of developing cancer before age 50.
The Colorectal Cancer Alliance is strengthening its commitment to Project Cure CRC, a nonprofit dedicated to ending the disease through innovative research and patient navigation. The organization has awarded three new grants and will present two poster sessions at the AACR Annual Meeting.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
Researchers have discovered RNA pseudouridine as a novel diagnostic target for colorectal cancer. The study found correlations between pseudouridine modifications and clinical markers, enabling potential non-invasive diagnosis. The findings provide a molecular framework for RNA epigenetics-based stratification and targeted interventions.
Researchers analyzed CRC tumors with high tumor mutation burden to characterize BRAF-associated mutations and decipher their role in carcinogenesis. They found TMB-high tumors likely arise from a heterogeneous population of cells harboring numerous gene mutations distinct from driver oncogenes.
A recent analysis found that rates of colorectal cancer diagnoses dropped during Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, but late-stage diagnoses eventually exceeded expectations. Limited access to cancer screening services due to these disasters likely hindered timely CRC diagnoses.
The study found an increase in pancreatic adenocarcinoma among all age groups, while a notable rise was observed in colorectal adenocarcinoma among younger patients. This trend highlights the importance of early detection and evaluation for clinicians when evaluating patients with relevant symptoms.
The study directly compared Droplet-based scRNA (D-scRNA) and Picowell-based scRNA (P-scRNA) platforms for analyzing human mucosal biopsies. D-scRNA provides more detailed insights, but requires resources and may introduce contamination. P-scRNA is gentler, more resource-efficient, but less effective in capturing rare cell types.
A Rice University-led team developed an implantable 'cytokine factory' that triggers potent immune responses against hard-to-treat cancers. The IL-12 cytokine factory successfully induces the recruitment of tumor-targeting T cells, eliminating local and distal tumors in preclinical models.
A new survey finds that eating hot dogs at baseball stadiums is common, but many people are unaware of the health risks associated with consuming processed meat. The survey found that tens of millions of Americans could eat hot dogs this baseball season, increasing their risk of colorectal cancer and other diseases.
A new study by Mass General Brigham researchers reveals that many eligible patients who receive other preventative screenings are not getting screened for lung cancer. The study found that 65% of those eligible received breast and colorectal cancer screening, a nearly 4-fold higher rate than lung cancer screening.
A study found that patient navigators significantly improved one-year follow-up colonoscopy completion rates by 12% and reduced time to follow-up by 27 days. The researchers emphasize the importance of timely follow-up colonoscopies for patients with abnormal stool test results.
Researchers developed a tiny magnetic robot that can take 3D scans from deep within the body, enabling 'virtual biopsies' for non-invasive cancer diagnosis and treatment. The device uses high-frequency imaging to create detailed 3D reconstructions, allowing clinicians to diagnose and treat colorectal cancer in a single procedure.
Recent studies by Regenstrief Institute and Indiana University School of Medicine found a sharp decline in colorectal cancer screening trends during the pandemic, followed by a rapid rebound. The impact was more pronounced on non-invasive testing, such as fecal immunochemical tests (FIT) and FIT/DNA tests, which declined but recovered ...
CU Cancer Center researchers discovered that H3K36 methylation regulates plasticity and regeneration in intestinal cells. The process, identified as a key 'switch', allows intestinal cells to regenerate after injury. This finding may lead to better treatments for colorectal cancer and other intestinal conditions.
A recent study has found that people diagnosed with colorectal cancer are more likely to die from cardiovascular causes, particularly in the first two years after diagnosis. The study analyzed data from over 630,000 US adults and found a 16% increased risk of cardiovascular mortality among those with colorectal cancer.
The study of 19,000 patients shows immune checkpoint inhibitors greatly improved survival rates for those living with MSI-H colorectal cancer. Researchers found factors that may improve therapy's effectiveness against MSS tumors under certain conditions.
A new clinical guideline from the American Gastroenterological Association suggests that artificial intelligence-assisted colonoscopy may improve polyp detection rates, but its impact on preventing colorectal cancer remains uncertain. The guideline recommends a cautious approach to widespread adoption, emphasizing the need for further ...
Researchers identify SPP1+ macrophages as critical in CRC development and metastasis, promoting EMT, hypoxia, glycolysis, and immunosuppression. Preoperative chemotherapy reduces SPP1 expression, highlighting a potential role in immunotherapy.
The ASCOLT trial found that aspirin does not statistically improve disease-free survival for all patients but demonstrates a consistent trend of improving overall and disease-free survival. Aspirin taken for up to 3 years is efficacious in patients with PIK3CA mutation, reducing recurrence by over 50%.
Researchers identified fibronectin and smooth muscle actin as associated with resistance to immunotherapy treatment. Cancer-associated fibroblasts produce these proteins, which contribute to the suppression of the anti-tumor immune response.
Researchers at the University of Texas at El Paso have developed a portable, blood-based device that can detect colon cancer using a biomarker called CCSP-2. The device has the potential to provide early detection and treatment options for this second-deadliest US cancer, making it a significant advancement in colorectal cancer screening.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
The updated recommendations from the US Multi-Society Task Force on Colorectal Cancer aim to achieve a benchmark of 90% exams with adequate bowel preparation. The guidelines focus on optimizing bowel preparation before, during, and after colonoscopy, including patient education, dietary restrictions, and choice of preparation agent.
Researchers developed a risk-prediction model based on four factors: family history, body mass index, sex, and smoking. A score equal to or greater than 9 indicates an above 14% likelihood of developing cancer or advanced precancerous lesions in adults under 45.
Researchers from the University of Toronto have shown that a low-carb diet can worsen the DNA-damaging effects of certain gut microbes, increasing the risk of colorectal cancer. A unique strain of E. coli bacteria was found to drive polyp growth in the colon when paired with a low-carb diet.
Researchers identified co-occurring genetic alterations in colorectal and pancreatic cancers that contribute to resistance to KRAS G12C inhibitors. These mutations can lead to poor prognosis and chemotherapy resistance.
A nationwide study found that patients with alcoholic liver disease have a significantly higher risk of developing colorectal cancer. The study highlights the importance of comprehensive CRC screening and risk stratification based on new consensus-based definitions of liver disease.
Researchers have discovered lipid signatures associated with chemotherapy-resistant cells in colorectal cancer. These lipid alterations can serve as prognostic markers and help develop new treatment strategies to restore drug sensitivity.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
Colorectal cancer is a leading cause of mortality in China due to late-stage diagnosis. Emerging non-invasive diagnostic tests, innovative imaging techniques, and AI applications enhance CRC detection and diagnosis. However, expanding accessibility and promoting public awareness remain key challenges.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Researchers found that long-term yogurt intake was associated with lower rates of proximal colon cancer positive for Bifidobacterium, a bacterial species found in yogurt. The study showed that higher yogurt consumption over time may protect against colorectal cancer through changes in the gut microbiome.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
Researchers discover Artemisia herba-alba extract stops cancer cell growth and causes them to die, with potential as a complementary treatment. The study highlights the plant's selective cytotoxicity against CRC cell lines, offering a promising natural ingredient for new cancer treatments.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
Researchers identified distinct molecular features of early onset colorectal cancer in racial and ethnic minorities, including widespread changes in DNA methylation and metabolic gene expression. These findings suggest that environmental risk factors such as diet and stress may contribute to the disparities in incidence and mortality a...